Current and future directions for treating hepatitis B virus infection

Table 2 Long-term treatment efficacy of peginterferon treatment in hepatitis B e antigen-positive chronic hepatitis B

Ref.	No. of patients	Formula of therapy	Seroconversion from HBeAg to anti-HBe (%)	Suppression of HBV DNA (%)	Normalization of ALT (%)	HBsAg loss (n)
cBuster et al[31]	91	Peg-IFNα-2b for 52 wk	35	25a	30	7 (8%)
	81	Peg-IFNα-2b plus LAM for 52 wk	25	31a	30	12 (15%)
dWong et al[32]	85	Peg-IFNα-2b for 32 wk plus LAM for 52 or 104 wk	60	13b	57	2 (2.4%)

a < 10000 copies/mL; b < 100 copies/mL. The treatment efficacies were assessed at approximately 3-year follow-up^c or approximately 5-year follow-up^d. LAM: Lamivudine; Peg-IFN: Peginterferon; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; ALT: Alanine aminotransferase.